Lipocine (LPCN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

LPCN Stock Forecast

Lipocine stock forecast is as follows: an average price target of $10.00 (represents a 100.00% upside from LPCN’s last price of $5.00) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

LPCN Price Target

The average price target for Lipocine (LPCN) is $10.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 100.00% upside from LPCN's last price of $5.00.

LPCN Analyst Ratings

Buy

According to 1 Wall Street analysts, Lipocine's rating consensus is 'Buy'. The analyst rating breakdown for LPCN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Lipocine Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Scott Henry	Industrial Alliance Securities	$10.00	$4.54	120.26%	100.00%

Row per page

Go to

The latest Lipocine stock forecast, released on Sep 24, 2024 by Scott Henry from Industrial Alliance Securities, set a price target of $10.00, which represents a 120.26% increase from the stock price at the time of the forecast ($4.54), and a 100.00% increase from LPCN last price ($5.00).

Lipocine Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$10.00	$10.00
Last Closing Price	$5.00	$5.00	$5.00
Upside/Downside	-100.00%	100.00%	100.00%

In the current month, the average price target of Lipocine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lipocine's last price of $5.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 24, 2024	Alliance Global Partners	-	Buy	Initialise

Row per page

Go to

Lipocine's last stock rating was published by Alliance Global Partners on Sep 24, 2024. The company Initialise its LPCN rating from "null" to "Buy".

Lipocine Financial Forecast

Lipocine Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	$-3.12M	-	$54.99K	$9.50M	-	$500.00K	-	$-38.85K	-	-	$428.03K	-	-
Avg Forecast	$2.87M	$999.00K	$624.00K	$500.00K	$1.35M	$129.50K	$290.00K	$307.00K	$256.00K	$777.00K	$1.31M	$698.67K	$257.00K	$4.00M	$5.50M	$21.00	$2.35K	$694.62K	$3.12K	$30.14K
High Forecast	$2.87M	$999.00K	$624.00K	$500.00K	$1.35M	$129.50K	$290.00K	$307.00K	$256.00K	$777.00K	$1.31M	$698.67K	$257.00K	$4.00M	$5.50M	$25.00	$2.82K	$833.54K	$3.75K	$36.17K
Low Forecast	$2.87M	$999.00K	$624.00K	$500.00K	$1.35M	$129.50K	$290.00K	$307.00K	$256.00K	$777.00K	$1.31M	$698.67K	$257.00K	$4.00M	$5.50M	$16.00	$1.88K	$555.69K	$2.50K	$24.11K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	3	5	8	15	12	8	11
Surprise %	-	-	-	-	-	-	-	-10.17%	-	0.07%	7.27%	-	1.95%	-	-0.01%	-	-	0.62%	-	-

Lipocine's average Quarter revenue forecast for Jun 24 based on 1 analysts is $290.00K, with a low forecast of $290.00K, and a high forecast of $290.00K. LPCN's average Quarter revenue forecast represents a -109.29% decrease compared to the company's last Quarter revenue of $-3.12M (Sep 23).

Lipocine EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	3	5	8	15	12	8	11
EBITDA	-	-	-	-	-	-	-	$-6.73M	$-3.57M	$-3.96M	$-2.26M	$-2.73M	$-3.46M	$-3.09M	$13.09M	$-5.64M	$-3.00M	$-2.52M	$-4.85M	$-7.00M
Avg Forecast	$-15.32K	$-5.33K	$-3.33K	$-2.67K	$-7.19K	$-690.00	$-1.55K	$-1.64K	$-1.36K	$-4.14K	$-6.97K	$27.23K	$10.02K	$-3.40M	$214.39K	$-9.19M	$-3.12M	$-3.48M	$-5.56M	$-5.74M
High Forecast	$-15.32K	$-5.33K	$-3.33K	$-2.67K	$-7.19K	$-690.00	$-1.55K	$-1.64K	$-1.36K	$-4.14K	$-6.97K	$27.23K	$10.02K	$-2.72M	$214.39K	$-7.35M	$-2.50M	$-2.79M	$-4.44M	$-4.59M
Low Forecast	$-15.32K	$-5.33K	$-3.33K	$-2.67K	$-7.19K	$-690.00	$-1.55K	$-1.64K	$-1.36K	$-4.14K	$-6.97K	$27.23K	$10.02K	$-4.08M	$214.39K	$-11.03M	$-3.75M	$-4.18M	$-6.67M	$-6.89M
Surprise %	-	-	-	-	-	-	-	4108.61%	2613.91%	956.17%	324.54%	-100.35%	-344.92%	0.91%	61.04%	0.61%	0.96%	0.72%	0.87%	1.22%

3 analysts predict LPCN's average Quarter EBITDA for Mar 22 to be $-3.40M, with a high of $-2.72M and a low of $-4.08M. This is -125.96% lower than Lipocine's previous annual EBITDA (Dec 21) of $13.09M.

Lipocine Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	3	5	8	15	12	8	11
Net Income	-	-	-	-	-	-	-	$-6.65M	$-3.55M	$-3.87M	$-2.23M	$-2.25M	$-1.74M	$-3.49M	$13.26M	$-5.77M	$-3.22M	$-2.72M	$-4.86M	$-7.01M
Avg Forecast	$-695.23K	$-1.50M	$-1.66M	$-1.71M	$-1.98M	$-2.59M	$-4.17M	$-3.21M	$-3.42M	$-2.27M	$-2.73M	$-3.03M	$-3.63M	$-3.84M	$-908.47K	$-11.54M	$-3.22M	$-3.76M	$-5.51M	$-5.70M
High Forecast	$-695.23K	$-1.50M	$-1.66M	$-1.71M	$-1.82M	$-2.59M	$-4.17M	$-3.21M	$-3.42M	$-2.27M	$-2.73M	$-3.03M	$-3.63M	$-3.07M	$-908.47K	$-9.23M	$-2.58M	$-3.00M	$-4.41M	$-4.56M
Low Forecast	$-695.23K	$-1.50M	$-1.66M	$-1.71M	$-2.14M	$-2.59M	$-4.17M	$-3.21M	$-3.42M	$-2.27M	$-2.73M	$-3.03M	$-3.63M	$-4.60M	$-908.47K	$-13.85M	$-3.87M	$-4.51M	$-6.61M	$-6.83M
Surprise %	-	-	-	-	-	-	-	2.07%	1.04%	1.70%	0.82%	0.74%	0.48%	0.91%	-14.59%	0.50%	1.00%	0.72%	0.88%	1.23%

Lipocine's average Quarter net income forecast for Mar 22 is $-3.84M, with a range of $-4.60M to $-3.07M. LPCN's average Quarter net income forecast represents a -128.94% decrease compared to the company's last Quarter net income of $13.26M (Dec 21).

Lipocine SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	3	5	8	15	12	8	11
SG&A	-	-	-	-	-	-	-	$1.04M	$1.44M	$1.29M	$890.34K	$798.94K	$1.13M	$1.24M	$-4.28M	$2.09M	$-773.39K	$309.96K	$-1.26M	$1.72M
Avg Forecast	$23.93M	$8.32M	$5.20M	$4.17M	$11.24M	$1.08M	$2.42M	$2.56M	$2.13M	$6.47M	$10.88M	$5.82M	$2.14M	$1.37M	$45.82M	$174.00	$-773.39K	$428.04K	$-1.43M	$251.14K
High Forecast	$23.93M	$8.32M	$5.20M	$4.17M	$11.24M	$1.08M	$2.42M	$2.56M	$2.13M	$6.47M	$10.88M	$5.82M	$2.14M	$1.64M	$45.82M	$208.00	$-618.72K	$513.65K	$-1.14M	$301.36K
Low Forecast	$23.93M	$8.32M	$5.20M	$4.17M	$11.24M	$1.08M	$2.42M	$2.56M	$2.13M	$6.47M	$10.88M	$5.82M	$2.14M	$1.09M	$45.82M	$133.00	$-928.07K	$342.44K	$-1.71M	$200.90K
Surprise %	-	-	-	-	-	-	-	0.41%	0.68%	0.20%	0.08%	0.14%	0.53%	0.91%	-0.09%	11984.26%	1.00%	0.72%	0.88%	6.86%

Lipocine's average Quarter SG&A projection for Jun 24 is $2.42M, based on 1 Wall Street analysts, with a range of $2.42M to $2.42M. The forecast indicates a 131.75% rise compared to LPCN last annual SG&A of $1.04M (Sep 23).

Lipocine EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	4	3	5	8	15	12	8	11
EPS	-	-	-	-	-	-	-	$-1.26	$-0.68	$-0.74	$-0.03	$-0.03	$-0.02	$-0.04	$0.15	$-0.14	$-0.14	$-0.13	$-0.26	$-0.38
Avg Forecast	$-0.13	$-0.28	$-0.31	$-0.32	$-0.37	$-0.48	$-0.78	$-0.60	$-0.64	$-0.42	$-0.51	$-0.57	$-0.68	$-0.34	$-0.17	$-1.36	$-2.46	$-0.29	$-0.34	$-0.26
High Forecast	$-0.13	$-0.28	$-0.31	$-0.32	$-0.34	$-0.48	$-0.78	$-0.60	$-0.64	$-0.42	$-0.51	$-0.57	$-0.68	$-0.34	$-0.17	$-1.36	$-2.46	$-0.23	$-0.27	$-0.21
Low Forecast	$-0.13	$-0.28	$-0.31	$-0.32	$-0.40	$-0.48	$-0.78	$-0.60	$-0.64	$-0.42	$-0.51	$-0.57	$-0.68	$-0.34	$-0.17	$-1.36	$-2.46	$-0.35	$-0.41	$-0.31
Surprise %	-	-	-	-	-	-	-	2.10%	1.06%	1.74%	0.05%	0.04%	0.03%	0.12%	-0.88%	0.10%	0.06%	0.45%	0.76%	1.46%

According to 3 Wall Street analysts, Lipocine's projected average Quarter EPS for Mar 22 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -326.67% decrease compared to LPCN previous annual EPS of $0.15 (Dec 21).

Lipocine Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
RVPH	Reviva Pharmaceuticals	$1.24	$10.00	706.45%	Buy
CKPT	Checkpoint Therapeutics	$3.47	$20.00	476.37%	Buy
KOD	Kodiak Sciences	$5.90	$31.60	435.59%	Buy
ZURA	Zura Bio	$2.93	$10.00	241.30%	Buy
VSTM	Verastem	$3.93	$8.33	111.96%	Buy
LPCN	Lipocine	$5.00	$10.00	100.00%	Buy
ARDX	Ardelyx	$5.12	$8.75	70.90%	Buy

LPCN Forecast FAQ

Is Lipocine a good buy?

Yes, according to 1 Wall Street analysts, Lipocine (LPCN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of LPCN's total ratings.

What is LPCN's price target?

Lipocine (LPCN) average price target is $10 with a range of $10 to $10, implying a 100.00% from its last price of $5. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Lipocine stock go up soon?

According to Wall Street analysts' prediction for LPCN stock, the company can go up by 100.00% (from the last price of $5 to the average price target of $10), up by 100.00% based on the highest stock price target, and up by 100.00% based on the lowest stock price target.

Can Lipocine stock reach $8?

LPCN's average twelve months analyst stock price target of $10 supports the claim that Lipocine can reach $8 in the near future.

What are Lipocine's analysts' financial forecasts?

Lipocine's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.77M (high $1.77M, low $1.77M), average EBITDA is $-9.43K (high $-9.43K, low $-9.43K), average net income is $-8.744M (high $-8.583M, low $-8.904M), average SG&A $14.73M (high $14.73M, low $14.73M), and average EPS is $-1.635 (high $-1.605, low $-1.665). LPCN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5M (high $5M, low $5M), average EBITDA is $-26.645K (high $-26.645K, low $-26.645K), average net income is $-5.562M (high $-5.562M, low $-5.562M), average SG&A $41.62M (high $41.62M, low $41.62M), and average EPS is $-1.04 (high $-1.04, low $-1.04).

Did the LPCN's actual financial results beat the analysts' financial forecasts?

Based on Lipocine's last annual report (Dec 2022), the company's revenue was $500K, which missed the average analysts forecast of $6.26M by -92.01%. Apple's EBITDA was $-11.547M, beating the average prediction of $-3.367M by 242.95%. The company's net income was $-10.759M, missing the average estimation of $-13.226M by -18.66%. Apple's SG&A was $4.06M, missing the average forecast of $20.21M by -79.90%. Lastly, the company's EPS was $-0.12, missing the average prediction of $-2.097 by -94.28%. In terms of the last quarterly report (Sep 2023), Lipocine's revenue was $-3.122M, missing the average analysts' forecast of $307K by -1116.94%. The company's EBITDA was $-6.726M, beating the average prediction of $-1.637K by 410761.15%. Lipocine's net income was $-6.651M, beating the average estimation of $-3.209M by 107.28%. The company's SG&A was $1.04M, missing the average forecast of $2.56M by -59.24%. Lastly, the company's EPS was $-1.26, beating the average prediction of $-0.6 by 110.00%